Natus Medical (NASDAQ:BABY) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $1.60-1.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.62. The company issued revenue guidance of $535-540 million, compared to the consensus revenue estimate of $536.88 million.Natus Medical also updated its Q2 guidance to $0.25-0.27 EPS.
BABY stock traded down $1.85 on Wednesday, reaching $34.05. The company’s stock had a trading volume of 172,001 shares, compared to its average volume of 506,737. Natus Medical has a 12-month low of $28.00 and a 12-month high of $43.60. The firm has a market capitalization of $1,193.78, a price-to-earnings ratio of 22.76 and a beta of 0.47. The company has a quick ratio of 2.54, a current ratio of 3.32 and a debt-to-equity ratio of 0.37.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings data on Wednesday, April 25th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.24. The business had revenue of $128.60 million during the quarter, compared to the consensus estimate of $125.91 million. Natus Medical had a positive return on equity of 11.36% and a negative net margin of 4.05%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.30 earnings per share. equities research analysts anticipate that Natus Medical will post 1.63 earnings per share for the current year.
Natus Medical declared that its board has initiated a share repurchase program on Thursday, February 22nd that permits the company to repurchase $30.00 million in shares. This repurchase authorization permits the medical equipment provider to reacquire shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.
BABY has been the subject of a number of research reports. Zacks Investment Research downgraded Natus Medical from a buy rating to a hold rating in a report on Tuesday, December 26th. BidaskClub downgraded Natus Medical from a sell rating to a strong sell rating in a report on Saturday, January 6th. William Blair downgraded Natus Medical from an outperform rating to a market perform rating in a report on Monday, January 8th. Benchmark reiterated a buy rating and issued a $49.00 price objective (down previously from $55.00) on shares of Natus Medical in a report on Tuesday, January 16th. Finally, Roth Capital set a $39.00 price objective on Natus Medical and gave the stock a buy rating in a report on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Natus Medical has a consensus rating of Buy and an average target price of $44.33.
In other Natus Medical news, Director Ken Ludlum sold 4,000 shares of the stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $31.68, for a total value of $126,720.00. Following the completion of the transaction, the director now owns 93,825 shares in the company, valued at $2,972,376. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 5.50% of the stock is currently owned by corporate insiders.
WARNING: “Natus Medical (BABY) Updates FY18 Earnings Guidance” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/25/natus-medical-baby-updates-fy18-earnings-guidance.html.
About Natus Medical
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.